MARKET

RAPP

RAPP

Rapport Therapeutics Inc
NASDAQ
33.91
+0.08
+0.24%
After Hours: 33.90 -0.01 -0.03% 19:30 09/25 EDT
OPEN
33.80
PREV CLOSE
33.83
HIGH
34.89
LOW
33.05
VOLUME
711.81K
TURNOVER
--
52 WEEK HIGH
52.93
52 WEEK LOW
23.75
MARKET CAP
1.63B
P/E (TTM)
-11.1542
1D
5D
1M
3M
1Y
5Y
1D
Show Me The Money: Rapport Stock Up Over 400% In 16 Months; Bipolar Mania Data Next
NASDAQ · 1d ago
Notable Thursday Option Activity: SGHC, RAPP, BE
NASDAQ · 1d ago
Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med - Rating Upgrade
Seeking Alpha · 2d ago
Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and The Estée Lauder Companies (EL)
TipRanks · 2d ago
RAPP: Buy Initiation Backed by RAP-219 Clinical Progress and Mechanistic Differentiation
TipRanks · 2d ago
Rapport drops after CEO presents at TD Cowen Neuropsychiatry Summit
TipRanks · 3d ago
Rapport Therapeutics Down Over 16%, on Pace for Largest Percent Decrease in Over a Year -- Data Talk
Dow Jones · 3d ago
Rapport Therapeutics: Great CNS Science, But The Valuation Prices In Significant Success
Seeking Alpha · 3d ago
More
About RAPP
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.

Webull offers Rapport Therapeutics Inc stock information, including NASDAQ: RAPP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RAPP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RAPP stock methods without spending real money on the virtual paper trading platform.